Emerging analgesic drugs for Parkinson's disease

Expert Opinion on Emerging Drugs

Volumn 17, Issue 2, 2012, Pages 157-171

  Perez Lloret, Santiago ^a,b,c   Rey, María Verónica ^a,c   Dellapina, Estelle ^b   Pellaprat, Jean ^b   Brefel Courbon, Christine ^a,b   Rascol, Olivier ^a,b  

^a UNIVERSITÉ PAUL SABATIER   (France)

^b CNRS   (France)

^c Instituto de Investigaciones Neurologicas Raul Carrera   (Argentina)

Author keywords

Analgesic treatments; Botulinum toxin; Cranial electrotherapy stimulation; Dopamine agonists; Duloxetine; Levodopa; Non motor symptoms; Outcome evaluation; Pain; Parkinson's disease; Patient selection; Repetitive transcranial magnetic stimulation; Surgical treatments for PD

Indexed keywords

ANALGESIC AGENT; APOMORPHINE; BOTULINUM TOXIN; BROMOCRIPTINE; DECARBOXYLASE INHIBITOR; DOPAMINE; DULOXETINE; ENTACAPONE; LEVODOPA; NALOXONE; OXYCODONE; PLACEBO; PRAMIPEXOLE; ROTIGOTINE; SELEGILINE;

ABDOMINAL PAIN; ANALGESIA; BACKACHE; BRAIN DAMAGE; BURNING MOUTH SYNDROME; CHRONIC PAIN; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; DYSTONIA; FIBROMYALGIA; FOLLOW UP; HUMAN; NEUROPATHIC PAIN; NOCICEPTIVE PAIN; NONHUMAN; PAIN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PATIENT SELECTION; PELVIS PAIN SYNDROME; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SUBTHALAMIC NUCLEUS; THORAX PAIN; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT OUTCOME;

ANALGESICS; ANIMALS; CLINICAL TRIALS AS TOPIC; DOUBLE-BLIND METHOD; HUMANS; PAIN; PAIN MANAGEMENT; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84861610583     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.2012.677949     Document Type: Review

References (115)

1. Poewe W. The natural history of Parkinson's disease. J Neurol 2006;253(Suppl 7):VII2-6
2. Andlin-Sobocki P, Jonsson B, Wittchen HU, et al. Cost of disorders of the brain in Europe. Eur J Neurol 2005;12(Suppl 1):1-27
3. Lang AE, Lozano AM. Parkinson's disease. First of two parts. N Engl J Med 1998;339:1044-53 (Pubitemid 28457867)
4. Jellinger KA. Neuropathology of sporadic Parkinson's disease: evaluation and changes of concepts. Mov Disord 2012;27:8-30
5. Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009;8:464-74
6. Martinez-Martin P. The importance of non-motor disturbances to quality of life in Parkinson's disease. J Neurol Sci 2011;310:12-16
7. Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, et al. The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease. Mov Disord 2011;26:399-406
8. Shearer J, Green C, Counsell CE, et al. The impact of motor and non motor symptoms on health state values in newly diagnosed idiopathic Parkinson's disease. J Neurol 2012;259(3):462-8
9. Del Sorbo F, Albanese A. Clinical management of pain and fatigue in Parkinson's disease. Parkinsonism Relat Disord 2012;18(Suppl 1):S233-6
10. Broen MP, Braaksma MM, Patijn J, et al. Prevalence of pain in Parkinson's disease: a systematic review using the modified QUADAS tool. Mov Disord 2012 Jan 9. doi: 10.1002/mds.24054
11. Beiske AG, Loge JH, Ronningen A, et al. Pain in Parkinson's disease: prevalence and characteristics. Pain 2009;141:173-7
12. Broetz D, Eichner M, Gasser T, et al. Radicular and nonradicular back pain in Parkinson's disease: a controlled study. Mov Disord 2007;22:853-6 (Pubitemid 46800109)
13. Defazio G, Berardelli A, Fabbrini G, et al. Pain as a nonmotor symptom of Parkinson disease: evidence from a case-control study. Arch Neurol 2008;65:1191-4
14. Etchepare F, Rozenberg S, Mirault T, et al. Back problems in Parkinson's disease: an underestimated problem. Joint Bone Spine 2006;73:298-302
15. Giuffrida R, Vingerhoets FJ, Bogousslavsky J, et al. Pain in Parkinson's disease. Rev Neurol (Paris) 2005;161:407-18 (Pubitemid 40562411)
16. Hanagasi HA, Akat S, Gurvit H, et al. Pain is common in Parkinson's disease. Clin Neurol Neurosurg 2011;113:11-13
17. Lee MA, Walker RW, Hildreth TJ, et al. A survey of pain in idiopathic Parkinson's disease. J Pain Symptom Manage 2006;32:462-9 (Pubitemid 44666294)
18. Negre-Pages L, Regragui W, Bouhassira D, et al. Chronic pain in Parkinson's disease: the cross-sectional French DoPaMiP survey. Mov Disord 2008;23:1361-9
19. Quittenbaum BH, Grahn B. Quality of life and pain in Parkinson's disease: a controlled cross-sectional study. Parkinsonism Relat Disord 2004;10:129-36 (Pubitemid 38251656)
20. Quinn NP, Koller WC, Lang AE, et al. Painful Parkinson's disease. Lancet 1986;1:1366-9 (Pubitemid 16121899)
21. Ford B. Pain in Parkinson's disease. Mov Disord 2010;25(Suppl 1):S98-103
22. Goetz CG, Tanner CM, Levy M, et al. Pain in Parkinson's disease. Mov Disord 1986;1:45-9
23. Brefel-Courbon C, Payoux P, Thalamas C, et al. Effect of levodopa on pain threshold in Parkinson's disease: a clinical and positron emission tomography study. Mov Disord 2005;20:1557-63
24. Djaldetti R, Shifrin A, Rogowski Z, et al. Quantitative measurement of pain sensation in patients with Parkinson disease. Neurology 2004;62:2171-5 (Pubitemid 38787770)
25. Lim SY, Farrell MJ, Gibson SJ, et al. Do dyskinesia and pain share common pathophysiological mechanisms in Parkinson's disease? Mov Disord 2008;23:1689-95
26. Mylius V, Engau I, Teepker M, et al. Pain sensitivity and descending inhibition of pain in Parkinson's disease. J Neurol Neurosurg Psychiatry 2009;80:24-8
27. Schestatsky P, Kumru H, Valls-Sole J, et al. Neurophysiologic study of central pain in patients with Parkinson disease. Neurology 2007;69:2162-9 (Pubitemid 350294696)
28. Tinazzi M, Del VC, Defazio G, et al. Abnormal processing of the nociceptive input in Parkinson's disease: a study with CO2 laser evoked potentials. Pain 2008;136:117-24 (Pubitemid 351491374)
29. Zambito Marsala S, Tinazzi M, Vitaliani R, et al. Spontaneous pain, pain threshold, and pain tolerance in Parkinson's disease. J Neurol 2011;258:627-33
30. Gerdelat-Mas A, Simonetta-Moreau M, Thalamas C, et al. Levodopa raises objective pain threshold in Parkinson's disease: a RIII reflex study. J Neurol Neurosurg Psychiatry 2007;78:1140-2
31. Perrotta A, Sandrini G, Serrao M, et al. Facilitated temporal summation of pain at spinal level in Parkinson's disease. Mov Disord 2011;26(3):442-8
32. Dellapina E, Gerdelat-Mas A, Ory-Magne F, et al. Apomorphine effect on pain threshold in Parkinson's disease: a clinical and positron emission tomography study. Mov Disord 2011;26:153-7
33. Kanda T, Tsukagoshi H, Oda M, et al. Changes of unmyelinated nerve fibers in sural nerve in amyotrophic lateral sclerosis, Parkinson's disease and multiple system atrophy. Acta Neuropathol 1996;91:145-54 (Pubitemid 26021401)
34. Nolano M, Provitera V, Estraneo A, et al. Sensory deficit in Parkinson's disease: evidence of a cutaneous denervation. Brain 2008;131:1903-11 (Pubitemid 351957457)
35. Roh JH, Kim BJ, Jang JH, et al. The relationship of pain and health-related quality of life in Korean patients with Parkinson's disease. Acta Neurol Scand 2009;119:397-403
36. Muller T, Muhlack S, Woitalla D. Pain perception, pain drug therapy and health status in patients with Parkinson's disease. Neuroepidemiology 2011;37:183-7
37. Grosset D, Taurah L, Burn DJ, et al. A multicentre longitudinal observational study of changes in self reported health status in people with Parkinson's disease left untreated at diagnosis. J Neurol Neurosurg Psychiatry 2007;78:465-9 (Pubitemid 46662892)
38. Ha AD, Jankovic J. Pain in Parkinson's disease. Mov Disord 2011 Sep 23. doi: 10.1002/mds.23959
39. Juri C, Rodriguez-Oroz M, Obeso JA. The pathophysiological basis of sensory disturbances in Parkinson's disease. J Neurol Sci 2010;289:60-5
40. Stacy M. The wearing-off phenomenon and the use of questionnaires to facilitate its recognition in Parkinson's disease. J Neural Transm 2010;117:837-46
41. Gordin A, Kaakkola S, Teravainen H. Clinical advantages of COMT inhibition with entacapone-a review. J Neural Transm 2004;111:1343-63 (Pubitemid 39468395)
42. Rabinak CA, Nirenberg MJ. Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol 2010;67:58-63
43. Dickey RP, Minton JP. Levodopa relief of bone pain from breast cancer. N Engl J Med 1972;286:843
44. Ertas M, Sagduyu A, Arac N, et al. Use of levodopa to relieve pain from painful symmetrical diabetic polyneuropathy. Pain 1998;75:257-9 (Pubitemid 28160136)
45. Kernbaum S, Hauchecorne J. Administration of levodopa for relief of herpes zoster pain. JAMA 1981;246:132-4 (Pubitemid 11122791)
46. Cobacho N, De la Calle JL, Gonzalez-Escalada JR, et al. Levodopa analgesia in experimental neuropathic pain. Brain Res Bull 2010;83:304-9
47. Olanow CW, Agid Y, Mizuno Y, et al. Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord 2004;19:997-1005 (Pubitemid 39302831)
48. Honig H, Antonini A, Martinez-Martin P, et al. Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord 2009;24:1468-74
49. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004;351:2498-508
50. Nebe A, Ebersbach G. Pain intensity on and off levodopa in patients with Parkinson's disease. Mov Disord 2009;24:1233-7
51. Stuginski-Barbosa J, Rodrigues GG, Bigal ME, et al. Burning mouth syndrome responsive to pramipexol. J Headache Pain 2008;9:43-5
52. Holman AJ, Myers RR. A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications. Arthritis Rheum 2005;52:2495-505 (Pubitemid 41117437)
53. Barone P, Poewe W, Albrecht S, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010;9:573-80
54. Katzenschlager R, Head J, Schrag A, et al. Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology 2008;71:474-80
55. Factor SA, Brown DL, Molho ES. Subcutaneous apomorphine injections as a treatment for intractable pain in Parkinson's disease. Mov Disord 2000;15:167-9 (Pubitemid 30038007)
56. Frankel JP, Lees AJ, Kempster PA, et al. Subcutaneous apomorphine in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry 1990;53:96-101 (Pubitemid 20067654)
57. Trenkwalder C, Kies B, Rudzinska M, et al. Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord 2011;26:90-9
58. Brefel-Courbon C, Grolleau S, Thalamas C, et al. Comparison of chronic analgesic drugs prevalence in Parkinson's disease, other chronic diseases and the general population. Pain 2009;141:14-18
59. Silva EG, Viana MA, Quagliato EM. Pain in Parkinson's disease: analysis of 50 cases in a clinic of movement disorders. Arq Neuropsiquiatr 2008;66:26-9 (Pubitemid 351520712)
60. Westanmo AD, Gayken J, Haight R. Duloxetine: a balanced and selective norepinephrine-and serotonin-reuptake inhibitor. Am J Health Syst Pharm 2005;62:2481-90 (Pubitemid 41720564)
61. Bellingham GA, Peng PW. Duloxetine: a review of its pharmacology and use in chronic pain management. Reg Anesth Pain Med 2010;35:294-303
62. Djaldetti R, Yust-Katz S, Kolianov V, et al. The effect of duloxetine on primary pain symptoms in Parkinson disease. Clin Neuropharmacol 2007;30:201-5 (Pubitemid 47356716)
63. Fox SH, Katzenschlager R, Lim SY, et al. The movement disorder society evidence-based medicine review update: treatments for the motor symptoms of Parkinson's disease. Mov Disord 2011;26(Suppl 3):S2-41
64. Witjas T, Kaphan E, Regis J, et al. Effects of chronic subthalamic stimulation on nonmotor fluctuations in Parkinson's disease. Mov Disord 2007;22:1729-34 (Pubitemid 47610462)
65. Kim HJ, Paek SH, Kim JY, et al. Chronic subthalamic deep brain stimulation improves pain in Parkinson disease. J Neurol 2008;255:1889-94
66. Krack P, Batir A, Van BN, et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 2003;349:1925-34 (Pubitemid 37409709)
67. Gierthmuhlen J, Arning P, Binder A, et al. Influence of deep brain stimulation and levodopa on sensory signs in Parkinson's disease. Mov Disord 2010;25:1195-202
68. Oshima H, Katayama Y, Morishita T, et al. Subthalamic nucleus stimulation for attenuation of pain related to Parkinson disease. J Neurosurg 2012;116:99-106
69. Juri C, Viviani P, Chana P. Features associated with the development of non-motor manifestations in Parkinson's disease. Arq Neuropsiquiatr 2008;66:22-5 (Pubitemid 351520711)
70. Samura K, Miyagi Y, Morioka T, et al. Intractable facial pain in advanced Parkinson's disease alleviated by subthalamic nucleus stimulation. J Neurol Neurosurg Psychiatry 2008;79:1410-11
71. Zibetti M, Torre E, Cinquepalmi A, et al. Motor and nonmotor symptom follow-up in parkinsonian patients after deep brain stimulation of the subthalamic nucleus. Eur Neurol 2007;58:218-23 (Pubitemid 350175889)
72. Kim HJ, Jeon BS, Paek SH. Effect of deep brain stimulation on pain in Parkinson disease. J Neurol Sci 2011;310:251-5
73. Laitinen LV, Bergenheim AT, Hariz MI. Leksell's posteroventral pallidotomy in the treatment of Parkinson's disease. J Neurosurg 1992;76:53-61
74. Honey CR, Stoessl AJ, Tsui JK, et al. Unilateral pallidotomy for reduction of parkinsonian pain. J Neurosurg 1999;91:198-201
75. Lefaucheur JP, Drouot X, Nguyen JP. Interventional neurophysiology for pain control: duration of pain relief following repetitive transcranial magnetic stimulation of the motor cortex. Neurophysiol Clin 2001;31:247-52 (Pubitemid 32885020)
76. Pridmore S, Oberoi G. Transcranial magnetic stimulation applications and potential use in chronic pain: studies in waiting. J Neurol Sci 2000;182:1-4
77. Reid P, Pridmore S. Improvement in chronic pain with transcranial magnetic stimulation. Aust NZ J Psychiatry 2001;35:252 (Pubitemid 32377551)
78. Lefaucheur JP, Drouot X, Keravel Y, et al. Pain relief induced by repetitive transcranial magnetic stimulation of precentral cortex. Neuroreport 2001;12:2963-5 (Pubitemid 32882016)
79. Andre-Obadia N, Peyron R, Mertens P, et al. Transcranial magnetic stimulation for pain control. Double-blind study of different frequencies against placebo, and correlation with motor cortex stimulation efficacy. Clin Neurophysiol 2006;117:1536-44
80. Lefaucheur JP, Ndre-Obadia N, Poulet E, et al. French guidelines on the use of repetitive transcranial magnetic stimulation (rTMS): safety and therapeutic indications. Neurophysiol Clin 2011;41:221-95
81. Leung A, Donohue M, Xu R, et al. rTMS for suppressing neuropathic pain: a meta-analysis. J Pain 2009;10:1205-16
82. O'Connell NE, Wand BM, Marston L, et al. Non-invasive brain stimulation techniques for chronic pain. Cochrane Database Syst Rev 2010 Sep 8;(9):CD008208
83. Khedr EM, Kotb H, Kamel NF, et al. Longlasting antalgic effects of daily sessions of repetitive transcranial magnetic stimulation in central and peripheral neuropathic pain. J Neurol Neurosurg Psychiatry 2005;76:833-8 (Pubitemid 40805815)
84. Bestmann S, Baudewig J, Siebner HR, et al. Functional MRI of the immediate impact of transcranial magnetic stimulation on cortical and subcortical motor circuits. Eur J Neurosci 2004;19:1950-62 (Pubitemid 38482583)
85. Garcia-Larrea L, Peyron R, Mertens P, et al. Electrical stimulation of motor cortex for pain control: a combined PET-scan and electrophysiological study. Pain 1999;83:259-73 (Pubitemid 29479285)
86. Peyron R, Faillenot I, Mertens P, et al. Motor cortex stimulation in neuropathic pain. Correlations between analgesic effect and hemodynamic changes in the brain. A PET study. Neuroimage 2007;34:310-21 (Pubitemid 44765250)
87. Nguyen JP, Nizard J, Keravel Y, et al. Invasive brain stimulation for the treatment of neuropathic pain. Nat Rev Neurol 2011;7:699-709
88. Maarrawi J, Peyron R, Mertens P, et al. Motor cortex stimulation for pain control induces changes in the endogenous opioid system. Neurology 2007;69:827-34 (Pubitemid 47329581)
89. Lomarev MP, Kanchana S, Bara-Jimenez W, et al. Placebo-controlled study of rTMS for the treatment of Parkinson's disease. Mov Disord 2006;21:325-31
90. Kodama M, Kasahara T, Hyodo M, et al. Effect of low-frequency repetitive transcranial magnetic stimulation combined with physical therapy on L-dopa-induced painful off-period dystonia in Parkinson's disease. Am J Phys Med Rehabil 2011;90:150-5
91. Wilson OB, Hamilton RF, Warner RL, et al. The influence of electrical variables on analgesia produced by low current transcranial electrostimulation of rats. Anesth Analg 1989;68:673-81 (Pubitemid 20041756)
92. Capel ID, Dorrell HM, Spencer EP, et al. The amelioration of the suffering associated with spinal cord injury with subperception transcranial electrical stimulation. Spinal Cord 2003;41:109-17 (Pubitemid 36174219)
93. Gabis L, Shklar B, Baruch YK, et al. Pain reduction using transcranial electrostimulation: a double blind "active placebo" controlled trial. J Rehabil Med 2009;41:256-61
94. Rintala DH, Tan G, Willson P, et al. Feasibility of using cranial electrotherapy stimulation for pain in persons with Parkinson's disease. Parkinsons Dis 2010;2010:569154
95. Twelves D, Perkins KS, Counsell C. Systematic review of incidence studies of Parkinson's disease. Mov Disord 2003;18:19-31 (Pubitemid 36150204)
96. von Campenhausen S, Bornschein B, Wick R, et al. Prevalence and incidence of Parkinson's disease in Europe. Eur Neuropsychopharmacol 2005;15:473-90 (Pubitemid 40949553)
97. Dorsey ER, Constantinescu R, Thompson JP, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007;68:384-6 (Pubitemid 46184217)
98. Cox H, Togasaki DM, Chen L, et al. The selective kappa-opioid receptor agonist U50,488 reduces L-dopa-induced dyskinesias but worsens parkinsonism in MPTP-treated primates. Exp Neurol 2007;205:101-7 (Pubitemid 46617495)
99. Iselin-Chaves IA, Grotzsch H, Besson M, et al. Naloxone-responsive acute dystonia and parkinsonism following general anaesthesia. Anaesthesia 2009;64:1359-62
100. Mellor K, Ahmed A, Thomson A. Tramadol hydrochloride use and acute deterioration in Parkinson's disease tremor. Mov Disord 2009;24:622-3
101. Zesiewicz TA, Hauser RA, Freeman A, et al. Fentanyl-induced bradykinesia and rigidity after deep brain stimulation in a patient with Parkinson disease. Clin Neuropharmacol 2009;32:48-50
102. Wu SC, Wrobel JS, Armstrong DG. Assessing the impact of pharmacologic intervention on the quality of life in diabetic peripheral neuropathic pain and fibromyalgia. Pain Med 2007;8(Suppl 2):S33-42 (Pubitemid 47288509)
103. Hoffman DL, Sadosky A, Dukes EM, et al. How do changes in pain severity levels correspond to changes in health status and function in patients with painful diabetic peripheral neuropathy? Pain 2010;149:194-201
104. Turk DC. Clinical effectiveness and cost-effectiveness of treatments for patients with chronic pain. Clin J Pain 2002;18:355-65 (Pubitemid 35291576)
105. Perez-Lloret S, Rojas GM, Menoni MC, et al. Pregabalin beneficial effects on sleep quality or health-related quality of life are poorly correlated with reduction on pain intensity after an 8-week treatment course. Clin Neuropharmacol 2012;35:21-4
106. Vane JR, Botting RM. The mechanism of action of aspirin. Thromb Res 2003;110:255-8 (Pubitemid 37329821)
107. Moulin DE, Max MB, Kaiko RF, et al. The analgesic efficacy of intrathecal D-Ala2-D-Leu5-enkephalin in cancer patients with chronic pain. Pain 1985;23:213-21 (Pubitemid 16200691)
108. Perez-Lloret S, Rascol O. Dopamine receptor agonists for the treatment of early or advanced Parkinson's disease. CNS Drugs 2010;24:941-68
109. Dworkin RH, Turk DC, Peirce-Sandner S, et al. Research design considerations for confirmatory chronic pain clinical trials: IMMPACT recommendations. Pain 2010;149:177-93
110. Dworkin RH, Turk DC, Farrar JT, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 2005;113:9-19 (Pubitemid 40038441)
111. Altman DG, Schulz KF, Moher D, et al. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 2001;134:663-94 (Pubitemid 32322245)
112. Martinez-Martin P, Jeukens-Visser M, Lyons KE, et al. Health-related quality-of-life scales in Parkinson's disease: critique and recommendations. Mov Disord 2011;26:2371-80
113. Jenkinson C, Fitzpatrick R, Peto V, et al. The Parkinson's disease questionnaire (PDQ-39): development and validation of a Parkinson's disease summary index score. Age Ageing 1997;26:353-7 (Pubitemid 27448379)
114. Schrag A. Psychiatric aspects of Parkinson's disease-an update. J Neurol 2004;251:795-804 (Pubitemid 39005962)
115. Schrag A. Apathy and depression scales in Parkinson's disease: are they good enough? J Neurol Sci 2011;310:216-19